Perfil
Denis G.
Bosc worked as a Senior Director, Operations Director, and Director of Manufacturing & Operations in various biotech companies from 2007 to 2012 and from 2008 to 2010.
He also worked as a Vice President of Chemistry, Manufacturing & Control in NervGen Pharma Corp.
in 2019-2020.
Bosc holds a doctorate degree from the University of Manitoba.
Antiguos cargos conocidos de Denis G. Bosc.
| Empresas | Cargo | Fin |
|---|---|---|
| NERVGEN PHARMA CORP. | Corporate Officer/Principal | 01/04/2020 |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | 01/10/2012 |
| SQI DIAGNOSTICS INC. | Corporate Officer/Principal | 01/08/2010 |
Viventia Biotech, Inc.
 Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Corporate Officer/Principal | 01/08/2008 |
Formación de Denis G. Bosc.
| University of Manitoba | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| SQI DIAGNOSTICS INC. | Health Technology |
| NERVGEN PHARMA CORP. | Health Technology |
| Empresas privadas | 2 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Viventia Biotech, Inc.
Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Health Technology |
- Bolsa de valores
- Insiders
- Denis G. Bosc
